
The APPLE trial, focusing on juvenile-onset systemic lupus erythematosus (JSLE), reveals distinct atherosclerosis progression patterns despite low cardiovascular risk. Unsupervised clustering identified high, intermediate, and low CIMT trajectories. A metabolomic signature predicts high CIMT progression in the placebo group. Atorvastatin reduced LDL, but 36% still had high progression, not predicted by metabolomic biomarkers, highlighting non-lipid factors.
Like
Save
Share